Abstract
Introduction
This analysis examines the historical and forecast performance for J&J in the
ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to purchase this research
- Benchmark Johnson & Johnson' s performance against key rivals in the
prescription pharmaceutical sector
- Analyze how J&J will implement life cycle management strategies across its
portfolio as a means to combat patent expiries and generic competition
- Assess J&J' s diverse healthcare offering and how this will act to maintain
operating profit growth despite a forecast decline in Rx drug revenue
| 
View Cart
